56 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • Therapy
  • Anergis SA

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • Therapy
  • Anergis SA

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • World
  • Product Initiative

PATIENTS WERE RANDOMIZED IN A ##:## FASHION TO ACTIVE DRUG VERSUS PLACEBO.

  • Allergy
  • Healthcare
  • Immunotherapy
  • Monoclonal Antibody
  • Therapy

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Healthcare
  • Monoclonal Antibody
  • Therapy

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Healthcare
  • Monoclonal Antibody
  • United States

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Healthcare
  • Monoclonal Antibody
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Healthcare
  • Monoclonal Antibody
  • Biomay AG

About ## percent of people who have food allergies are allergic to more than one food.

  • Allergy
  • Healthcare
  • Medical Biotechnology
  • Monoclonal Antibody
  • Product Initiative

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • World
  • Product Initiative

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • Japan
  • Product Initiative

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Allergy
  • Healthcare
  • Immunotherapy
  • Monoclonal Antibody
  • Product Initiative

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Allergy
  • Healthcare
  • Medical Biotechnology
  • Monoclonal Antibody
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Healthcare
  • Monoclonal Antibody
  • Product Initiative

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy
  • Allergy Drug
  • Healthcare
  • Monoclonal Antibody
  • Ophthalmic Solution

Oneness Biotech Co Ltd (Oneness Biotech) is a biopharmaceutical company that conducts research and development of drugs.

  • Allergy
  • Chronic Disease
  • Healthcare
  • Monoclonal Antibody
  • Glenmark Pharmaceuticals Ltd.

These drugs are useful for treatment of inflammatory diseases, allergy, pain, , asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria etc.

  • Allergy
  • Antifungal
  • Ear Disease
  • Healthcare
  • Therapy

The data were presented at the European Academy of Allergy and Clinical Immunology ##th Annual Congress 2016.

  • Allergy
  • Antifungal
  • Ear Disease
  • Healthcare
  • Therapy

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Allergy
  • Antifungal
  • Blood Disease
  • Healthcare
  • Monoclonal Antibody

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Allergy
  • Antifungal
  • Healthcare
  • Monoclonal Antibody
  • United States

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • Respiratory Disease
  • Therapy

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • Therapy
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Allergy
  • Cell Therapy
  • Healthcare
  • Monoclonal Antibody
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Allergy
  • Antifungal
  • Digestive System Disorder
  • Healthcare
  • Monoclonal Antibody

About ## percent of people who have food allergies are allergic to more than one food.

  • Allergy
  • Healthcare
  • Monoclonal Antibody
  • Therapy
  • United States

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Allergy
  • Antifungal
  • Ear Disease
  • Healthcare
  • Therapy

IT WAS ALSO UNDER DEVELOPMENT FORAUTOIMMUNE DISEASES AND ALLERGIES.

  • Acne Treatment
  • Allergy
  • Healthcare
  • Pharmaceutical
  • Therapy

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy
  • Allergy Drug
  • Healthcare
  • Monoclonal Antibody
  • Ophthalmic Solution

The drug candidate acts by blocking the histamine receptors and prevents the excess mucus production associated with ocular allergy.

  • Allergy
  • Antifungal
  • Ear Disease
  • Healthcare
  • Therapy

Rituximab was well tolerated, and most adverse drug reactions were grade ##-## in severity.

  • Allergy
  • Autoimmune Disease
  • Healthcare
  • Monoclonal Antibody
  • Therapy